• Epizyme Inc., of Cambridge, Mass., said it signed a deal with Abbott, of Abbott Park, Ill., to develop a molecular companion diagnostic test for use with EPZ-5676, its inhibitor targeting the DOT1L histone methyltransferase for the treatment of mixed lineage leukemia.